Search

for
Search:

GlossaryNivolumab (Opdivo)

immunotherapy drug that helps immune system attack cancer cells

Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1 on the surface of T-cells, which helps the immune system recognize and attack cancer cells more effectively.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 10 results

research Anti-Programmed Cell Death Protein 1-Induced Lichenoid Changes of the Nail Unit: Histopathologic Description

12 citations , March 2021 in “JAAD Case Reports”

Nail changes from immunotherapy can be managed without stopping cancer treatment.

research Eosinophilic Folliculitis of the Scalp Associated with PD-1/PDL1 Inhibitors

9 citations , April 2020 in “Journal of Cosmetic Dermatology”

Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.

research Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

November 2022 in “Journal of the Endocrine Society”

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

research An Industry Update: What's New in the Field of Therapeutic Delivery This Month?

November 2016 in “Therapeutic Delivery”

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

research Cutaneous Toxicity as a Predictive Biomarker for Clinical Outcome in Patients Receiving Anticancer Therapy

32 citations , May 2018 in “Journal of the American Academy of Dermatology”

Skin reactions from cancer treatments might predict how well the treatments work.

View more "opdivo" in research →

Community Join

0 / 0 results

— no results